Published in Cancer Res on November 28, 2014
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | NCT00670748
T cell metabolism drives immunity. J Exp Med (2015) 2.06
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Targeting T cell metabolism for therapy. Trends Immunol (2015) 1.27
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity (2016) 1.26
mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation. J Clin Invest (2015) 1.18
Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest (2015) 0.96
BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. Nat Immunol (2016) 0.93
Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol (2015) 0.88
Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. Cell Mol Immunol (2015) 0.85
Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol (2015) 0.84
Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84
Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression. Front Immunol (2016) 0.81
Regulatory circuits of T cell function in cancer. Nat Rev Immunol (2016) 0.81
BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest (2016) 0.80
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. Mol Ther (2016) 0.80
Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94. Curr Top Med Chem (2016) 0.79
Special Conference on Tumor Immunology and Immunotherapy: A New Chapter. Cancer Immunol Res (2015) 0.79
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discov (2016) 0.79
Exploiting IL-17-producing CD4(+) and CD8(+) T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother (2016) 0.79
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol (2016) 0.78
Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. Cancer Immunol Res (2016) 0.77
Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin Immunol (2015) 0.77
Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity. BMC Cancer (2015) 0.77
Time to Akt: Superior tumor-reactive T cells for adoptive immunotherapy. Oncoimmunology (2015) 0.76
Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. Curr Opin Immunol (2017) 0.76
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J Immunother Cancer (2017) 0.75
Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. Oncoimmunology (2016) 0.75
Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. Vaccines (Basel) (2016) 0.75
Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology (2016) 0.75
CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells. Immunology (2015) 0.75
β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. JCI Insight (2017) 0.75
Targeting Akt in cell transfer immunotherapy for cancer. Oncoimmunology (2015) 0.75
Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight (2017) 0.75
Dynamic Metabolism in Immune Response. J Immunol Res Ther (2016) 0.75
Akt signaling is critical for memory CD8(+) T-cell development and tumor immune surveillance. Proc Natl Acad Sci U S A (2017) 0.75
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol (2017) 0.75
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab (2017) 0.75
PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8(+) T Cells. Front Immunol (2017) 0.75
mTOR signaling in growth control and disease. Cell (2012) 29.21
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 8.09
Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science (2002) 6.01
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity (2011) 5.43
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol (2012) 4.44
Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today (2008) 3.49
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. J Neurochem (2009) 2.92
Quantitative microplate-based respirometry with correction for oxygen diffusion. Anal Chem (2009) 2.86
The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 2.85
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50
Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur J Immunol (2003) 2.31
Metabolism, migration and memory in cytotoxic T cells. Nat Rev Immunol (2011) 2.25
Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. J Neurosci (2007) 2.23
Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity (2011) 2.17
Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol (2009) 2.15
Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity (2014) 2.09
Bioenergetic profile experiment using C2C12 myoblast cells. J Vis Exp (2010) 1.96
CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc Natl Acad Sci U S A (2013) 1.90
Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci U S A (2010) 1.85
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
Protective capacity of memory CD8+ T cells is dictated by antigen exposure history and nature of the infection. Immunity (2011) 1.53
Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol (2012) 1.48
CD4+ and CD8+ T cell survival is regulated differentially by protein kinase Ctheta, c-Rel, and protein kinase B. J Immunol (2007) 1.18
Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol (2013) 1.13
From cancer immunosurveillance to cancer immunotherapy. Immunol Rev (2007) 1.10
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev (2014) 1.03
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res (2014) 1.01
The expansion and maintenance of antigen-selected CD8(+) T cell clones. Adv Immunol (2007) 0.93
mTORC1 regulates CD8+ T-cell glucose metabolism and function independently of PI3K and PKB. Biochem Soc Trans (2013) 0.83